Eli Lilly Delays Approval Filing for Obesity Drug Retatrutide Until Q1 2027
Eli Lilly announced it will file for regulatory approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027 after successfully completing two late-stage trials. The drug showed significant weight loss and improved blood sugar levels in adults with obesity and related conditions.
Tickers: $LLY